Evidence map›Paper›PMID 37426418›Full record

ArticleFrontiers in molecular biosciences2023

Pyridylnidulin exerts anti-diabetic properties and improves non-alcoholic fatty liver disease in diet-induced obesity mice.

Sutharinee Likitnukul, Surapun Tepaarmorndech, Theerayuth Kaewamatawong, Arunrat Yangchum, Chanathip Duangtha, Pimrapat Jongjang, Supachoke Mangmool, Darawan Pinthong, Masahiko Isaka

Open access · goldAbstract read
In one paragraph

Article in Frontiers in molecular biosciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.8field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
  3. Pharmaceuticals (Basel, Switzerland) · 2024
    Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Sutharinee LikitnukulDepartment of Pharmacology, Faculty of Science, Mahidol University, Bangkok, Thailand.
Surapun TepaarmorndechFaculty of Medicine, Chulalongkorn University, Bangkok, Thailand.
Theerayuth KaewamatawongDepartment of Pathology, Faculty of Veterinary Science, Chulalongkorn University, Bangkok, Thailand.
Arunrat YangchumNational Center for Genetic Engineering and Biotechnology (BIOTEC), National Science and Technology Development Agency (NSTDA), Pathumthani, Thailand.
Chanathip DuangthaDepartment of Pharmacology, Faculty of Science, Mahidol University, Bangkok, Thailand.
Pimrapat JongjangDepartment of Pharmacology, Faculty of Science, Mahidol University, Bangkok, Thailand.
Supachoke MangmoolDepartment of Pharmacology, Faculty of Science, Mahidol University, Bangkok, Thailand.
Darawan PinthongDepartment of Pharmacology, Faculty of Science, Mahidol University, Bangkok, Thailand.
Masahiko IsakaNational Center for Genetic Engineering and Biotechnology (BIOTEC), National Science and Technology Development Agency (NSTDA), Pathumthani, Thailand.
Mahidol University · THChulalongkorn University · THNational Center for Genetic Engineering and Biotechnology · TH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

anti-diabeticdiabetesmetabolic disordersnon-alcoholic fatty liver diseaseobesitypyridylnidulin

Identifiers

PMID37426418
PMCPMC10324605
OpenAlexW4381805110

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.